Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT04632758 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: WX-0593 Tablets
DRUG: crizotinib

Sponsor

Qilu Pharmaceutical Co., Ltd.